RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Bellerophon Therapeutics Stock

Bellerophon Therapeutics Market capitalization 2024

Bellerophon Therapeutics Market capitalization

343,831.32 USD

Ticker

BLPH

ISIN

US0787713009

WKN

A2PZZR

In 2024, Bellerophon Therapeutics's market cap stood at 343,831.32 USD, a -88.79% increase from the 3.07 M USD market cap in the previous year.

The Bellerophon Therapeutics Market capitalization history

YEARMarket Capitalization (undefined USD)
202214.41
202151.1
202079.35
201940.48
2018113.53
201752.82
201625.56
201579.33
2014-
2013-
2012-

Bellerophon Therapeutics Aktienanalyse

What does Bellerophon Therapeutics do?

Bellerophon Therapeutics Inc is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of lung diseases. The company was founded in 2009 and is headquartered in Warren, New Jersey. Bellerophon's business model is based on the research and development of therapies for the treatment of severe respiratory diseases, particularly pulmonary hypertension (PH) and chronic obstructive pulmonary disease (COPD). The company works closely with leading researchers and clinicians to develop innovative treatments that can improve the lives of patients with lung diseases. Bellerophon has several divisions aimed at expanding the portfolio of lung diseases. The first division is the development of INOpulse®, a therapy that improves lung function through inhaled nitric oxide (NO). This therapy specializes in the treatment of PH and has already been approved by the FDA in the United States, the European Commission, and other regulatory agencies worldwide. Another division of Bellerophon is the development of treatments using ultra-short-acting beta-agonists (uBAs), which are able to relax the respiratory muscles and improve breathing. This therapy specializes in the treatment of COPD and is based on a novel device designed to improve the effectiveness of uBA therapy. Bellerophon also has several programs in the pipeline for the development of therapies for the treatment of other lung diseases, including pulmonary fibrosis, lung cancer, and cystic fibrosis. These programs are still in the research phase but have the potential to bring forth new innovations in the future. Some of Bellerophon's products include INOpulse®, an inhaled nitric oxide treatment for PH, and the novel device that improves the effectiveness of uBA therapy for COPD. Additionally, the company is working on further product developments in the field of lung diseases. Overall, Bellerophon Therapeutics Inc has already made significant progress in the development of innovative therapies to improve lung function, particularly in the treatment of PH and COPD. With a strong pipeline of products and programs focused on exploring new therapies for the treatment of lung diseases, the company will continue to expand its position in the field of lung diseases and improve the lives of patients with severe respiratory diseases. Bellerophon Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Market capitalization Details

Exploring Bellerophon Therapeutics's Market Capitalization

Bellerophon Therapeutics's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Bellerophon Therapeutics's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Bellerophon Therapeutics's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Bellerophon Therapeutics’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Bellerophon Therapeutics stock

What is the current Bellerophon Therapeutics market capitalization?

The current market capitalization of Bellerophon Therapeutics is 343,831.32 USD.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Bellerophon Therapeutics.

How has the market capitalization of Bellerophon Therapeutics developed in recent years?

The market capitalization of Bellerophon Therapeutics has increased/decreased by -88.79% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of Bellerophon Therapeutics?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of Bellerophon Therapeutics?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of Bellerophon Therapeutics have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does Bellerophon Therapeutics pay?

Over the past 12 months, Bellerophon Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Bellerophon Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Bellerophon Therapeutics?

The current dividend yield of Bellerophon Therapeutics is .

When does Bellerophon Therapeutics pay dividends?

Bellerophon Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Bellerophon Therapeutics?

Bellerophon Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Bellerophon Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Bellerophon Therapeutics located?

Bellerophon Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Bellerophon Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Bellerophon Therapeutics from 10/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/1/2024.

When did Bellerophon Therapeutics pay the last dividend?

The last dividend was paid out on 10/1/2024.

What was the dividend of Bellerophon Therapeutics in the year 2023?

In the year 2023, Bellerophon Therapeutics distributed 0 USD as dividends.

In which currency does Bellerophon Therapeutics pay out the dividend?

The dividends of Bellerophon Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Bellerophon Therapeutics

Our stock analysis for Bellerophon Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bellerophon Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.